Recent progress in mRNA cancer vaccines
The research and development of messenger RNA (mRNA) cancer vaccines have gradually overcome numerous challenges through the application of personalized cancer antigens, structural optimization of mRNA, and the development of alternative RNA-based vectors and efficient targeted delivery vectors. Cli...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2307187 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849717231545483264 |
|---|---|
| author | Ruhui Yao Chunyuan Xie Xiaojun Xia |
| author_facet | Ruhui Yao Chunyuan Xie Xiaojun Xia |
| author_sort | Ruhui Yao |
| collection | DOAJ |
| description | The research and development of messenger RNA (mRNA) cancer vaccines have gradually overcome numerous challenges through the application of personalized cancer antigens, structural optimization of mRNA, and the development of alternative RNA-based vectors and efficient targeted delivery vectors. Clinical trials are currently underway for various cancer vaccines that encode tumor-associated antigens (TAAs), tumor-specific antigens (TSAs), or immunomodulators. In this paper, we summarize the optimization of mRNA and the emergence of RNA-based expression vectors in cancer vaccines. We begin by reviewing the advancement and utilization of state-of-the-art targeted lipid nanoparticles (LNPs), followed by presenting the primary classifications and clinical applications of mRNA cancer vaccines. Collectively, mRNA vaccines are emerging as a central focus in cancer immunotherapy, offering the potential to address multiple challenges in cancer treatment, either as standalone therapies or in combination with current cancer treatments. |
| format | Article |
| id | doaj-art-a9fb222de0864a46a1ee40d98524e5cd |
| institution | DOAJ |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-a9fb222de0864a46a1ee40d98524e5cd2025-08-20T03:12:43ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2307187Recent progress in mRNA cancer vaccinesRuhui Yao0Chunyuan Xie1Xiaojun Xia2State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, ChinaState Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, ChinaThe research and development of messenger RNA (mRNA) cancer vaccines have gradually overcome numerous challenges through the application of personalized cancer antigens, structural optimization of mRNA, and the development of alternative RNA-based vectors and efficient targeted delivery vectors. Clinical trials are currently underway for various cancer vaccines that encode tumor-associated antigens (TAAs), tumor-specific antigens (TSAs), or immunomodulators. In this paper, we summarize the optimization of mRNA and the emergence of RNA-based expression vectors in cancer vaccines. We begin by reviewing the advancement and utilization of state-of-the-art targeted lipid nanoparticles (LNPs), followed by presenting the primary classifications and clinical applications of mRNA cancer vaccines. Collectively, mRNA vaccines are emerging as a central focus in cancer immunotherapy, offering the potential to address multiple challenges in cancer treatment, either as standalone therapies or in combination with current cancer treatments.https://www.tandfonline.com/doi/10.1080/21645515.2024.2307187mRNA vaccinelipid nanoparticlescancer vaccinestumor antigenspersonalized therapy |
| spellingShingle | Ruhui Yao Chunyuan Xie Xiaojun Xia Recent progress in mRNA cancer vaccines Human Vaccines & Immunotherapeutics mRNA vaccine lipid nanoparticles cancer vaccines tumor antigens personalized therapy |
| title | Recent progress in mRNA cancer vaccines |
| title_full | Recent progress in mRNA cancer vaccines |
| title_fullStr | Recent progress in mRNA cancer vaccines |
| title_full_unstemmed | Recent progress in mRNA cancer vaccines |
| title_short | Recent progress in mRNA cancer vaccines |
| title_sort | recent progress in mrna cancer vaccines |
| topic | mRNA vaccine lipid nanoparticles cancer vaccines tumor antigens personalized therapy |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2307187 |
| work_keys_str_mv | AT ruhuiyao recentprogressinmrnacancervaccines AT chunyuanxie recentprogressinmrnacancervaccines AT xiaojunxia recentprogressinmrnacancervaccines |